PE20161364A1 - CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS - Google Patents
CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSASInfo
- Publication number
- PE20161364A1 PE20161364A1 PE2016001895A PE2016001895A PE20161364A1 PE 20161364 A1 PE20161364 A1 PE 20161364A1 PE 2016001895 A PE2016001895 A PE 2016001895A PE 2016001895 A PE2016001895 A PE 2016001895A PE 20161364 A1 PE20161364 A1 PE 20161364A1
- Authority
- PE
- Peru
- Prior art keywords
- cyano
- halogen
- chromene
- methyl
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se refiere a compuestos de formula I o sales farmaceuticamente aceptables de los mismos, donde: A es A1, A2, entre otros; X es heteroarilo de 5 a 14 miembros que contiene 1 a 3 heteroatomos; R1 es hidrogeno, halogeno, ciano, entre otros; R2a y R2b son independientemente hidrogeno, fluor, ciano, entre otros; o R2a y R2b juntos forman un clicloalquilo C3-C8 o heterocicloalquilo C4-C10 sustituidos; R4a, R4b, R5a y R5b son independientemente hidrogeno, hidroxi, entre otros; o R4a y R4b juntos y R5a y R5b juntos forman un cicloalquilo C3-C8 sustituido; R6 y R7 son hidrogeno, ciano, halogeno, entre otros; z es 1 o 2; y y m son 1, 2, 3 o 4; n es 0 o 2; W es carbono u oxigeno; R10 es halogeno, ciano, hidroxi, entre otros; R11 es halogeno, ciano, entre otros; R12 es halogeno, ciano, hidroxi, entre otros. Son compuestos preferidos: 2-[(6-Cloro-8-fluoro-2,2-dimetil-2H-cromeno-4-il)metil]-7-(4-metil-1H-imidazol-1-il)-3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona; 2-{[2,2-Dimetil-6-(trifluorometil)-2H-cromeno-4-il]metil}-7-(4-metil-1H-imidazol-1-il)-3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona; entre otros. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos compuestos son utiles en el tratamiento de trastornos neurologicos y neurodegenerativos como la enfermedad de Alzheimer, entre otros
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461973436P | 2014-04-01 | 2014-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161364A1 true PE20161364A1 (es) | 2016-12-25 |
Family
ID=52815058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001895A PE20161364A1 (es) | 2014-04-01 | 2015-03-18 | CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS |
Country Status (30)
Country | Link |
---|---|
US (2) | US20150274721A1 (es) |
EP (1) | EP3126361B1 (es) |
JP (1) | JP6643247B2 (es) |
KR (1) | KR101886945B1 (es) |
CN (1) | CN106211770B (es) |
AP (1) | AP2016009465A0 (es) |
AR (1) | AR099874A1 (es) |
AU (1) | AU2015242330B2 (es) |
BR (1) | BR112016022519A8 (es) |
CA (1) | CA2944308A1 (es) |
CL (1) | CL2016002422A1 (es) |
CR (1) | CR20160454A (es) |
CU (1) | CU20160140A7 (es) |
DK (1) | DK3126361T3 (es) |
DO (1) | DOP2016000266A (es) |
EA (1) | EA031419B1 (es) |
EC (1) | ECSP16078289A (es) |
ES (1) | ES2759277T3 (es) |
HK (1) | HK1231481A1 (es) |
IL (1) | IL248154B (es) |
MD (1) | MD20160102A2 (es) |
MX (1) | MX369074B (es) |
NI (1) | NI201600149A (es) |
PE (1) | PE20161364A1 (es) |
PH (1) | PH12016501864A1 (es) |
SG (1) | SG11201607465UA (es) |
TW (1) | TWI568733B (es) |
UY (1) | UY36054A (es) |
WO (1) | WO2015150957A1 (es) |
ZA (1) | ZA201606252B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
PE20171318A1 (es) * | 2015-02-03 | 2017-09-07 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas |
CN106580997B (zh) * | 2016-12-09 | 2018-01-19 | 张田 | 一种治疗先兆流产的药物组合物 |
RU2757276C2 (ru) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
CN112996789A (zh) * | 2018-09-12 | 2021-06-18 | 诺华股份有限公司 | 抗病毒吡啶并吡嗪二酮化合物 |
CN110907542A (zh) * | 2018-09-17 | 2020-03-24 | 复旦大学 | 一种液质联用检测唾液中司来吉兰及其代谢物的方法 |
WO2020179859A1 (ja) | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
AU2020353055B2 (en) | 2019-09-26 | 2024-03-07 | Gilead Sciences, Inc. | Antiviral pyrazolopyridinone compounds |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
JP3816111B2 (ja) | 1997-04-09 | 2006-08-30 | インテレクト・ニューロサイエンシズ・インコーポレーテッド | β−アミロイド末端に特異的な組換え抗体、それをコードするDNA及びその使用法 |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
BRPI0108676B8 (pt) | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
EP1335738A4 (en) | 2000-11-03 | 2004-09-08 | Proteotech Inc | METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS |
EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
BR0308109A (pt) * | 2002-02-28 | 2005-01-04 | Sanofi Aventis | Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
EP1633786A4 (en) | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
WO2005025616A1 (ja) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | 抗体の用途 |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
EP2298807A3 (en) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
NZ564187A (en) | 2005-05-12 | 2010-03-26 | Pfizer | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
US7812040B2 (en) | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
AU2007242555B2 (en) | 2006-04-21 | 2010-12-16 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
PT2124933E (pt) | 2007-01-22 | 2013-01-07 | Pfizer Prod Inc | Sal tosilato de um composto terapêutico e composições farmacêuticas do mesmo |
JP2012506857A (ja) * | 2008-10-23 | 2012-03-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合複素環式m1受容体ポジティブアロステリック調節因子 |
WO2012131539A1 (en) * | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
AU2013261023B2 (en) * | 2012-05-16 | 2016-11-24 | Cellzome Limited | Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease |
UA110688C2 (uk) * | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
EP2945944B1 (en) * | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
CA2925743C (en) * | 2013-10-04 | 2018-03-06 | Pfizer Inc. | Novel bicyclic pyridinones as gamma-secretase modulators |
-
2015
- 2015-03-18 MD MDA20160102A patent/MD20160102A2/ro not_active Application Discontinuation
- 2015-03-18 CN CN201580018466.7A patent/CN106211770B/zh not_active Expired - Fee Related
- 2015-03-18 EA EA201600619A patent/EA031419B1/ru not_active IP Right Cessation
- 2015-03-18 CR CR20160454A patent/CR20160454A/es unknown
- 2015-03-18 PE PE2016001895A patent/PE20161364A1/es not_active Application Discontinuation
- 2015-03-18 JP JP2016559879A patent/JP6643247B2/ja not_active Expired - Fee Related
- 2015-03-18 ES ES15714951T patent/ES2759277T3/es active Active
- 2015-03-18 DK DK15714951.9T patent/DK3126361T3/da active
- 2015-03-18 MX MX2016012904A patent/MX369074B/es active IP Right Grant
- 2015-03-18 AU AU2015242330A patent/AU2015242330B2/en not_active Ceased
- 2015-03-18 KR KR1020167030135A patent/KR101886945B1/ko active IP Right Grant
- 2015-03-18 WO PCT/IB2015/051988 patent/WO2015150957A1/en active Application Filing
- 2015-03-18 AP AP2016009465A patent/AP2016009465A0/en unknown
- 2015-03-18 BR BR112016022519A patent/BR112016022519A8/pt not_active IP Right Cessation
- 2015-03-18 SG SG11201607465UA patent/SG11201607465UA/en unknown
- 2015-03-18 CA CA2944308A patent/CA2944308A1/en not_active Withdrawn
- 2015-03-18 EP EP15714951.9A patent/EP3126361B1/en active Active
- 2015-03-27 US US14/670,746 patent/US20150274721A1/en not_active Abandoned
- 2015-03-27 UY UY0001036054A patent/UY36054A/es not_active Application Discontinuation
- 2015-03-27 AR ARP150100922A patent/AR099874A1/es unknown
- 2015-03-31 TW TW104110551A patent/TWI568733B/zh not_active IP Right Cessation
-
2016
- 2016-09-09 ZA ZA2016/06252A patent/ZA201606252B/en unknown
- 2016-09-22 PH PH12016501864A patent/PH12016501864A1/en unknown
- 2016-09-22 CU CUP2016000140A patent/CU20160140A7/es unknown
- 2016-09-27 CL CL2016002422A patent/CL2016002422A1/es unknown
- 2016-09-29 DO DO2016000266A patent/DOP2016000266A/es unknown
- 2016-09-29 NI NI201600149A patent/NI201600149A/es unknown
- 2016-09-29 IL IL248154A patent/IL248154B/en active IP Right Grant
- 2016-09-30 EC ECIEPI201678289A patent/ECSP16078289A/es unknown
-
2017
- 2017-02-24 US US15/441,882 patent/US20170166566A1/en not_active Abandoned
- 2017-05-24 HK HK17105246.2A patent/HK1231481A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20161364A1 (es) | CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS | |
PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
PE20170128A1 (es) | Compuestos para tratar atrofia muscular espinal | |
PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
PE20141557A1 (es) | Derivado de pirazoloquinolina | |
PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
PE20170011A1 (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
PE20161021A1 (es) | Derivados heterociclicos biciclicos como inhibidores de bromodominio | |
ECSP10010506A (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A. | |
UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
NZ705040A (en) | Fused pyrimidines as inhibitors of p97 complex | |
UY29301A1 (es) | Derivados amida | |
DOP2011000260A (es) | Pirimidinas fusionadas | |
EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
CL2017001001A1 (es) | Derivados de carbazaol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |